Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Jan 8

PMID 39766036

Authors

Carrie Wemyss

Emily Jones

Regis Stentz

Simon R Carding

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) remain significant challenges in haematological oncology. This review examines the pathophysiology, classification, and risk stratification of these aggressive malignancies, emphasising their impact on treatment strategies and prognosis. We discuss current standard-of-care treatments, including chemotherapy regimens and targeted therapies, while addressing the associated adverse effects and hypersensitivity reactions. Delving into the metabolic characteristics and vulnerabilities of leukaemia cells, the review highlights the key differences between lymphoid and myeloid leukaemia and how metabolic insights can be utilised for therapeutic purposes, with special focus on asparaginase therapy and its potential for improvement in both ALL and AML treatment. The review conveys the importance of personalised medicine approaches based on individual metabolic profiles and the challenges posed by metabolic heterogeneity and plasticity in leukaemia cells. Combining molecular and metabolic profiling can enhance and refine treatment strategies for acute leukaemia, potentially improving patient outcomes and quality of life. However, integrating these into routine clinical practice requires overcoming various practical, technical, and logistical issues.

Citing Articles

Diagnostic and Therapeutic Implications of the SUMOylation Pathway in Acute Myeloid Leukemia.

Chatzikalil E, Arvanitakis K, Filippatos F, Diamantopoulos P, Koufakis T, Solomou E Cancers (Basel). 2025; 17(4).

PMID: 40002226 PMC: 11853134. DOI: 10.3390/cancers17040631.

References

Chan W, Horvath T, Tan L, Link T, Harutyunyan K, Pontikos M . Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2019; 18(9):1587-1592. PMC: 6726508. DOI: 10.1158/1535-7163.MCT-18-1329. View

Anderson K, Lutz C, van Delft F, Bateman C, Guo Y, Colman S . Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2010; 469(7330):356-61. DOI: 10.1038/nature09650. View

Di Giacomo D, La Starza R, Gorello P, Pellanera F, Atak Z, De Keersmaecker K . 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia. Blood. 2021; 138(9):773-784. PMC: 8513670. DOI: 10.1182/blood.2020010510. View

Faderl S, Kantarjian H, Talpaz M, Estrov Z . Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998; 91(11):3995-4019. View

DiNardo C, Stein E, de Botton S, Roboz G, Altman J, Mims A . Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018; 378(25):2386-2398. DOI: 10.1056/NEJMoa1716984. View

Wu C, Ning H, Liu M, Lin J, Luo S, Zhu W . Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J Clin Invest. 2018; 128(8):3425-3438. PMC: 6063469. DOI: 10.1172/JCI97973. View

Buaboonnam J, Cao X, Pauley J, Pui C, Ribeiro R, Rubnitz J . Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2013; 60(7):1161-4. PMC: 4005561. DOI: 10.1002/pbc.24470. View

Hlozkova K, Pecinova A, Alquezar-Artieda N, Pajuelo-Reguera D, Simcikova M, Hovorkova L . Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase. BMC Cancer. 2020; 20(1):526. PMC: 7275298. DOI: 10.1186/s12885-020-07020-y. View

Li D, Liang J, Yang W, Guo W, Song W, Zhang W . A distinct lipid metabolism signature of acute myeloid leukemia with prognostic value. Front Oncol. 2022; 12:876981. PMC: 9359125. DOI: 10.3389/fonc.2022.876981. View

10.

Gomber S, Dewan P, Chhonker D . Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr. 2009; 77(1):97-100. DOI: 10.1007/s12098-009-0254-3. View

11.

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

12.

Lubbert M, Ruter B, Claus R, Schmoor C, Schmid M, Germing U . A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2011; 97(3):393-401. PMC: 3291594. DOI: 10.3324/haematol.2011.048231. View

13.

Yurttas N, Eskazan A . Dasatinib-induced pulmonary arterial hypertension. Br J Clin Pharmacol. 2018; 84(5):835-845. PMC: 5903230. DOI: 10.1111/bcp.13508. View

14.

Naka R, Kondo T, Nishikubo M, Muranushi H, Ueda Y, Oka T . Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment. Am J Hematol. 2023; 98(9):E251-E254. DOI: 10.1002/ajh.27012. View

15.

Esparza S, Muluneh B, Galeotti J, Matson M, Richardson D, Montgomery N . Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia. Br J Haematol. 2019; 188(1):173-177. PMC: 7574315. DOI: 10.1111/bjh.16235. View

16.

Willems L, Jacque N, Jacquel A, Neveux N, Trovati Maciel T, Lambert M . Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood. 2013; 122(20):3521-32. PMC: 3829119. DOI: 10.1182/blood-2013-03-493163. View

17.

Galicia-Vazquez G, Smith S, Aloyz R . Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition. Blood Cancer J. 2018; 8(1):13. PMC: 5802573. DOI: 10.1038/s41408-017-0039-2. View

18.

Hernandez-Espinosa D, Minano A, Martinez C, Perez-Ceballos E, Heras I, Fuster J . L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol. 2006; 169(1):142-53. PMC: 1698772. DOI: 10.2353/ajpath.2006.051238. View

19.

Chen T, Zhang J, Zeng H, Zhang Y, Zhang Y, Zhou X . Antiproliferative effects of L-asparaginase in acute myeloid leukemia. Exp Ther Med. 2020; 20(3):2070-2078. PMC: 7401243. DOI: 10.3892/etm.2020.8904. View

20.

Wang Y, Ronckers C, van Leeuwen F, Moskowitz C, Leisenring W, Armstrong G . Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nat Med. 2023; 29(9):2268-2277. PMC: 10504074. DOI: 10.1038/s41591-023-02514-1. View